Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	454
Overall Study	STARTED	Mirabegron 50 mg	442
Overall Study	STARTED	Mirabegron 100 mg	433
Overall Study	Safety Analysis Set (SAF)	Placebo	453
Overall Study	Safety Analysis Set (SAF)	Mirabegron 50 mg	442
Overall Study	Safety Analysis Set (SAF)	Mirabegron 100 mg	433
Overall Study	Full Analysis Set (FAS)	Placebo	433
Overall Study	Full Analysis Set (FAS)	Mirabegron 50 mg	425
Overall Study	Full Analysis Set (FAS)	Mirabegron 100 mg	412
Overall Study	Full Analysis Set Incontinence (FAS-I)	Placebo	325
Overall Study	Full Analysis Set Incontinence (FAS-I)	Mirabegron 50 mg	312
Overall Study	Full Analysis Set Incontinence (FAS-I)	Mirabegron 100 mg	296
Overall Study	COMPLETED	Placebo	385
Overall Study	COMPLETED	Mirabegron 50 mg	383
Overall Study	COMPLETED	Mirabegron 100 mg	380
Overall Study	NOT COMPLETED	Placebo	69
Overall Study	NOT COMPLETED	Mirabegron 50 mg	59
Overall Study	NOT COMPLETED	Mirabegron 100 mg	53

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00662909/flow